financetom
Business
financetom
/
Business
/
PRESS DIGEST- Financial Times - August 7
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PRESS DIGEST- Financial Times - August 7
Aug 6, 2025 8:11 PM

Aug 7 (Reuters) - The following are the top stories in

the Financial Times. Reuters has not verified these stories and

does not vouch for their accuracy.

Headlines

- Glencore ( GLCNF ) to stay in London after shelving plans for New

York listing

- Britain demands China explain redacted parts of London

embassy plan

- Novartis weighs deal for biotech Avidity to boost drug

pipeline

- Generali sets up showdown vote for Mediobanca's future

- One in five British doctors are considering quitting,

regulator warns

- No evidence of bullying or harassment at Prince Harry

charity, watchdog finds

Overview

- Global miner and trader Glencore ( GLCNF ) said that

company has decided against moving its British listing to the

United States.

- Britain's Deputy Prime Minister Angela Rayner has demanded

additional information from China over its plans for a new

"mega" embassy in London after several of the drawings contained

areas that were blacked out.

- Swiss drugmaker Novartis has approached U.S.

biotech Avidity Biosciences ( RNA ) for a potential takeover

offer.

- Italy's top insurer Generali said it would

continue to assess Mediobanca's bid to buy Banca

Generali, as well as a revised distribution agreement

with the private bank, which is a key part of the offer.

- Britain's General Medical Council said that a fifth of

doctors are considering leaving the profession and urged

ministers to radically improve career prospects for medics.

- Britain's charity regulator said it had found no evidence

of bullying at a charity set up by Prince Harry, but criticised

all parties for allowing a dispute to become public.

(Compiled by Bengaluru newsroom)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Copyright 2023-2026 - www.financetom.com All Rights Reserved